IOVANCE BIOTHERAPEUTICS, INC. 4

Chief Commercial Officer Daniel Gordon Kirby had 10,001 RSUs in Iovance Biotherapeutics, Inc. vest into common stock and 2,436 shares withheld for taxes, resulting in 154,511 common shares and 60,003 RSUs owned post-transaction.

On August 10, 2026, Iovance Biotherapeutics, Inc. Chief Commercial Officer Daniel Gordon Kirby had 10,001 restricted stock units vest into an equivalent number of common shares, followed by the issuer withholding 2,436 shares at an implied price of $6.40 per share to cover mandatory tax obligations. These transactions were reported as a derivative-to-non-derivative conversion (code M) and a tax withholding (code F), not as open-market trades. After giving effect to the RSU vesting and the tax-share withholding, Kirby beneficially owned 154,511 shares of common stock directly and retained 60,003 RSUs from the February 10, 2025 grant outstanding and scheduled to vest in equal quarterly installments. The activity represents routine equity compensation vesting rather than a discretionary purchase or sale.

Filing Facts

CIK

1425205

Ticker

IOVA

Form

4

Source Type

fda

Accession

0001104659-26-095040

Alert Tier

5